Literature DB >> 743219

The molecular-weight-dependence of the anti-coagulant activity of heparin.

T C Laurent, A Tengblad, L Thunberg, M Höök, U Lindahl.   

Abstract

It is proposed that the anti-coagulant activity of heparin is related to the probability of finding, in a random distribution of different disaccharides, a dodecasaccharide with the sequence required for binding to antithrombin. It is shown that this probability is a function of the degree of polymerization of heparin. The hypothesis has been been tested with a series of narrow-molecular-weight-range fractions ranging from 5,600 to 36,000. The fractions having mol.wts. below 18,000 (comprising 85% of the original preparation) followed the predicted probability relationship as expressed by the proportion of molecules capable of binding to antithrombin. The probability that any randomly chosen dodecasaccharide sequence in heparin should bind to antithrombin was calculated to 0.022. The fraction with mol.wt. 36,000 contained proteoglycan link-region fragments, which may explain the deviation of the high-molecular-weight fractions from the hypothetical relationship. The relationship between anti-coagulant activity and molecular weight cannot be explained solely on the basis of availability of binding sites for antithrombin. The activity of high-affinity heparin (i.e. molecules containing high-affinity binding sites for antithrombin), determined either by a whole-blood clotting procedure or by thrombin inactivation in the presence of antithrombin, thus remained dependent on molecular weight. Possible explanations of this finding are discussed. One explanation could be a requirement for binding of thrombin to the heparin chain adjacent to antithrombin.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 743219      PMCID: PMC1186120          DOI: 10.1042/bj1750691

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  38 in total

1.  Macromolecular properties and biological activity of heparin.

Authors:  G H BARLOW; N D SANDERSON; P D McNEILL
Journal:  Arch Biochem Biophys       Date:  1961-09       Impact factor: 4.013

2.  A BIOLOGICAL, CHEMICAL AND PHYSICAL COMPARISON OF HEPARIN FROM DIFFERENT MAMMALIAN SPECIES.

Authors:  G H BARLOW; L J COEN; M M MOZEN
Journal:  Biochim Biophys Acta       Date:  1964-11-01

3.  THE ROLE OF SERINE IN THE LINKAGE OF HEPARIN TO PROTEIN.

Authors:  U LINDAHL; J A CIFONELLI; B LINDAHL; L RODEN
Journal:  J Biol Chem       Date:  1965-07       Impact factor: 5.157

4.  A modified uronic acid carbazole reaction.

Authors:  T BITTER; H M MUIR
Journal:  Anal Biochem       Date:  1962-10       Impact factor: 3.365

5.  Studies on fractionated heparin.

Authors:  T C LAURENT
Journal:  Arch Biochem Biophys       Date:  1961-02       Impact factor: 4.013

6.  Aliphatic ammonium salts in the assay of acidic polysaccharides from tissues.

Authors:  J E SCOTT
Journal:  Methods Biochem Anal       Date:  1960

7.  Structure and biosynthesis of heparin-like polysaccharides.

Authors:  U Lindahl; M Höök; G Bäckström; I Jacobsson; J Riesenfeld; A Malmström; L Rodén; D S Feingold
Journal:  Fed Proc       Date:  1977-01

8.  Structural requirements for the interaction of heparin with antithrombin III.

Authors:  J Riensenfeld; M Höök; I Björk; U Lindahl; B Ajaxon
Journal:  Fed Proc       Date:  1977-01

9.  Inhibition of activated factor XII by antithrombin-heparin cofactor.

Authors:  N Stead; A P Kaplan; R D Rosenberg
Journal:  J Biol Chem       Date:  1976-11-10       Impact factor: 5.157

10.  Purification of thrombin by affinity chromatography on immobilized heparin.

Authors:  B Nordenman; I Björk
Journal:  Thromb Res       Date:  1977-12       Impact factor: 3.944

View more
  45 in total

1.  Fractionation of heparin by chromatography on a tissue plasminogen activator-Sepharose column.

Authors:  P Andrade-Gordon; S Strickland
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

2.  Defining the domains of type I collagen involved in heparin- binding and endothelial tube formation.

Authors:  S M Sweeney; C A Guy; G B Fields; J D San Antonio
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

3.  Direct evidence for a predominantly exolytic processive mechanism for depolymerization of heparin-like glycosaminoglycans by heparinase I.

Authors:  S Ernst; A J Rhomberg; K Biemann; R Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

4.  The N-terminal segment of antithrombin acts as a steric gate for the binding of heparin.

Authors:  H L Fitton; R Skinner; T R Dafforn; L Jin; R N Pike
Journal:  Protein Sci       Date:  1998-03       Impact factor: 6.725

Review 5.  A historical perspective of the biophysics of the thrombin-heparin system: an example of nonspecific binding and the consequent parking problem in action.

Authors:  Donald J Winzor
Journal:  Biophys Rev       Date:  2013-02-14

Review 6.  Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  R Davis; D Faulds
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

7.  Binding of heparin to human platelet factor 4.

Authors:  S W Cowan; E N Bakshi; K J Machin; N W Isaacs
Journal:  Biochem J       Date:  1986-03-01       Impact factor: 3.857

8.  Kinetic analysis of the heparin-enhanced plasmin--antithrombin III reaction. Apparent catalytic role of heparin.

Authors:  R Machovich; P I Bauer; P Arányi; E Kecskés; K G Büki; I Horváth
Journal:  Biochem J       Date:  1981-12-01       Impact factor: 3.857

9.  Analysis of affinity and structural selectivity in the binding of proteins to glycosaminoglycans: development of a sensitive electrophoretic approach.

Authors:  M K Lee; A D Lander
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

10.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4.

Authors:  D A Lane; J Denton; A M Flynn; L Thunberg; U Lindahl
Journal:  Biochem J       Date:  1984-03-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.